

# Ultrasound contrast agents to facilitate sonothrombolysis in patients with acute myocardial infarction

<b>Submission date</b> 20/12/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 20/12/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 20/08/2021	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr O Kamp

### Contact details

VU University Medical Centre  
Department of Cardiology, 6D-120  
P.O. Box 7057  
Amsterdam  
Netherlands  
1007 MB  
+31 (0)20 444 2244  
o.kamp@vumc.nl

## Additional identifiers

### Protocol serial number

N/A

## Study information

Scientific Title

Ultrasound contrast agents to facilitate sonothrombolysis in patients with acute myocardial infarction

## **Acronym**

ULYSIS

## **Study objectives**

The optimal treatment strategy in patients with Acute Myocardial Infarction (AMI) is immediate restoration of coronary blood flow. Although thrombolytic therapy is the most widely used therapy, Percutaneous Coronary Intervention (PCI) is the treatment of choice in AMI patients, however, its widespread use is hampered by limited availability of specialised facilities and trained staff. There is a need for simpler and low-risk methods for effective recanalisation of thrombosed arteries that can be initiated early in the disease process.

Recently, the application of ultrasound in combination with thrombolytic agents was found to enhance thrombus dissolution in vitro and in vivo. In vivo studies using thrombo-occlusive canine and rabbit models demonstrated that Ultrasound Contrast Agents (UCAs) enhance this thrombus dissolving effect of ultrasound, resulting in higher recanalisation rates of occluded arteries.

## **Hypothesis:**

Under influence of ultrasound, UCAs enhance dissolution of thrombus in patients with acute ST-elevation myocardial infarction premedicated with aspirin and clopidogrel.

## **Ethics approval required**

Old ethics approval format

## **Ethics approval(s)**

Not provided at time of registration

## **Study design**

Randomised, placebo controlled, parallel group, single blinded multicentre trial

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Acute myocardial infarction

## **Interventions**

After having received 150 - 325 mg aspirin and a loading dose of 300 mg clopidogrel, patients will be randomised to:

1. Ultrasound application with infusion of an ultrasound contrast agent, or
2. Control (infusion of saline without ultrasound application).

Immediately after ultrasound application, catheterisation will be performed.

## **Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Aspirin and clopidogrel

**Primary outcome(s)**

Comparison of the UCA-group and the control group with respect to:

1. Patency of the culprit coronary artery
2. Thrombolysis In Myocardial Infarction (TIMI)-flow
3. Corrected TIMI frame count
4. Myocardial blush grade

**Key secondary outcome(s)**

1. ST-segment resolution
2. Release of cardiac enzymes
3. Echocardiographic wall motion score index
4. Safety

**Completion date**

01/12/2006

## **Eligibility**

**Key inclusion criteria**

1. Age 18 to 80 years
2. Diagnosed with acute myocardial infarction according to the criteria of the American College of Cardiology
3. Informed consent

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

Not Specified

**Key exclusion criteria**

1. Previous myocardial infarction
2. Clinical instability

3. Pregnancy/breast feeding
4. Known pulmonary hypertension
5. Known allergy to Optison
6. Any reason judged by the investigators to hamper inclusion

**Date of first enrolment**

01/10/2005

**Date of final enrolment**

01/12/2006

## Locations

**Countries of recruitment**

Netherlands

**Study participating centre**

VU University Medical Centre

Amsterdam

Netherlands

1007 MB

## Sponsor information

**Organisation**

VU University Medical Centre (The Netherlands)

**ROR**

<https://ror.org/00q6h8f30>

## Funder(s)

**Funder type**

Not defined

**Funder Name**

Not provided at time of registration

## Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		01/02/2012	20/08/2021	Yes	No
<a href="#">Protocol article</a>		08/03/2011	20/08/2021	Yes	No